medigraphic.com
ISSN 0016-3813 (Print)

2014, Number 6

<< Back Next >>

Gac Med Mex 2014; 150 (6)

Cancer genomes: where do we go from here?

Meléndez-Zajgla J, Maldonado LV

Language: Spanish
References: 54
Page: 563-569
PDF size: 251.85 Kb.


ABSTRACT

In recent years there has been an exponential growth of knowledge of the molecular basis of cancer. In particular, the creation of important initiatives for the elucidation of the genomes of several types of cancer has allowed for the first time the creation of catalogs for most mutational events in diverse tumors, which opens up significant opportunities for oncology and public health. This review provides an overview of the progress and possible directions in Mexico.


REFERENCES

  1. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893-8.

  2. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214-20.

  3. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046): 1157-60.

  4. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405-9.

  5. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-9. J. Meléndez-Zajgla,V. Maldonado: Genomas del cáncer. ¿Hacia dónde ir? 569

  6. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-6.

  7. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-20.

  8. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879-84.

  9. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5.

  10. The Cancer Genome Atlas. Disponible en: http://cancergenome.nih.gov/.

  11. International Cancer Genome Consortium. Disponible en: http://www. icgc.org.

  12. Ojesina AI. Landscape of genomic alterations in cervical cancer. En revisión.

  13. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-8.

  14. Sistemas de Proyectos. Instituto Nacional de Medicina Genómica; 2013.

  15. Barrera H. Comunicación personal. 2013.

  16. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013;31(15):1849-57.

  17. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373-83.

  18. Tursz T, Andre F, Lazar V, Lacroix L, Soria JC. Implications of personalized medicine--perspective from a cancer center. Nat Rev Clin Oncol. 2011;8(3):177-83.

  19. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 2011;17(6):528-36.

  20. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol. 2013;31(15):1815-24.

  21. Vui-Kee K, Mohd Dali AZ, Mohamed Rose I, Ghazali R, Jamal R, Mokhtar NM. Molecular markers associated with nonepithelial ovarian cancer in formalin-fixed, paraffin-embedded specimens by genome wide expression profiling. Kaohsiung J Med Sci. 2012;28(5):243-50.

  22. Nadauld L, Regan JF, Miotke L, et al. Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Transl Med (Sunnyvale). 2012;2(2).

  23. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif). 2013;6:287-303.

  24. Kim SY, Speed TP. Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics. 2013;14:189.

  25. Tarczy-Hornoch P, Amendola L, Aronson SJ, et al. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genet Med. 2013;15(10):824-32.

  26. Lunshof JE, Bobe J, Aach J, et al. Personal genomes in progress: from the human genome project to the personal genome project. Dialogues Clin Neurosci. 2010;12(1):47-60.

  27. Institut National du Cancer. Molecular genetic tests for access to targeted therapies in france in 2012. En: Activity Reports and Assessment. 2012.

  28. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893-8.

  29. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214-20.

  30. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046): 1157-60.

  31. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405-9.

  32. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-9.

  33. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-6.

  34. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-20.

  35. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879-84.

  36. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5.

  37. The Cancer Genome Atlas. Disponible en: http://cancergenome.nih.gov/.

  38. International Cancer Genome Consortium. Disponible en: http://www. icgc.org.

  39. Ojesina AI. Landscape of genomic alterations in cervical cancer. En revisión.

  40. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-8.

  41. Sistemas de Proyectos. Instituto Nacional de Medicina Genómica; 2013.

  42. Barrera H. Comunicación personal. 2013.

  43. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013;31(15):1849-57.

  44. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373-83.

  45. Tursz T, Andre F, Lazar V, Lacroix L, Soria JC. Implications of personalized medicine--perspective from a cancer center. Nat Rev Clin Oncol. 2011;8(3):177-83.

  46. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 2011;17(6):528-36.

  47. MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol. 2013;31(15):1815-24.

  48. Vui-Kee K, Mohd Dali AZ, Mohamed Rose I, Ghazali R, Jamal R, Mokhtar NM. Molecular markers associated with nonepithelial ovarian cancer in formalin-fixed, paraffin-embedded specimens by genome wide expression profiling. Kaohsiung J Med Sci. 2012;28(5):243-50.

  49. Nadauld L, Regan JF, Miotke L, et al. Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Transl Med (Sunnyvale). 2012;2(2).

  50. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif). 2013;6:287-303.

  51. Kim SY, Speed TP. Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics. 2013;14:189.

  52. Tarczy-Hornoch P, Amendola L, Aronson SJ, et al. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genet Med. 2013;15(10):824-32.

  53. Lunshof JE, Bobe J, Aach J, et al. Personal genomes in progress: from the human genome project to the personal genome project. Dialogues Clin Neurosci. 2010;12(1):47-60.

  54. Institut National du Cancer. Molecular genetic tests for access to targeted therapies in france in 2012. En: Activity Reports and Assessment. 2012.




2020     |     www.medigraphic.com